CDX Models for Oncology Studies
Our cell line-derived xenograft (CDX) model studies can be offered as subcutaneous, disseminated, or orthotopic in both mice and rats, and can also be used in our humanized models for evaluating immunotherapies within an intact human immune system.
Cell Line-Derived Xenograft - Cancer Model Database
Support your in vitro, in vivo, and ex vivo studies with the following at your fingertips:
- New user-friendly search and easy-to-navigate menus
- New model data, including HLA typing, growth curves, and tumor images
- New multi-parameter search options for all tumor model types (PDX and CDX)
Human tumor CDX models involve implantation of commercially available tumor cell lines or patient-derived xenograft-derived cell lines into immunodeficient mice to conduct in vivo efficacy evaluation of potential cancer therapies, including targeted therapy, cytotoxic drugs, antibody therapies, and viral therapies.
Our broad range of tumor lines gives you a wide variety of testing alternatives for your agent. We evaluate our xenograft model portfolio on a regular basis for response to standards of care to aid the design of combination studies.
Cell Line Derived Xenograft (CDX) Model
Figure 1: Diagram of Cell Line-Derived Xenograft, CDX Model
In addition to helping you select the most appropriate CDX model for your agent, our scientific staff can fully profile your agent in a variety of tumor types or in combination with the appropriate clinical agent.
Charles River offers a wide range of histotypes, including broad models like non-small cell lung cancer, breast cancer or colon cancer, as well as tumor models with a high medical need like ovarian cancer, leukemia, lymphoma, or prostate cancer.
MODELS WITH PROFILE
Histotype Cell Line* Bladder SW780 Brain U87 MG, U251 Breast BT474, HCC-1806, HCC-1954, JIMT-1, MCF-7, MDA-MB-231, HCC70, MDA-MB436 Colon CL-34, COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo, LS-174T, LS411N, RKO, SW48, SW480, SW620 Endocervical KB Epithelial A-431 Ewing's Sarcoma RD-ES Gastric N87, SNU-5, OE19 Head and Neck FaDu Leukemia HL-60, MOLM-13, MOLT-4, MV4-11, RS4;11, SET2, THP-1, HEL92.1.7, Kasumi-1, K562, OCI-AML3, MEC-1 Liver HuH-7, SNU-398, Hep3B Lung (Non-small cell) A-427, A549, H1299, H1975, H226, H23, H292, H460, H520, H522, H647, H727, H810, HCC-44, NCI-H2122, H1568, SK-MES-1, H1650 Lung (Small cell) H69, H82, H211, H526, SHP-77, DMS 114 Lymphoma Daudi, DoHH-2, Granta 519, JEKO-1, KARPAS-299, Mino, MOLT-4, Raji B, Ramos, REC-1, RL, SU-DHL-4, WSU-DLCL2, Namalwa Melanoma A2058, A375, IGR-37, UACC-62 Mesothelioma MSTO-211H Multiple Myeloma H929, OPM-2, RPMI 8226 Neuroblastoma SK-N-AS Ovarian A2780, IGR0V1, OVCAR-3, OVCAR-5, SK-OV-3, TOV-21G, OV-90 Pancreas BxPc-3, HPAC, HPAF II, KP4, MIA PaCa-2, PSN-1, PANC1 Prostate 22Rv.1, PC3, DU145 Renal 786-0, G-401, G-402 Sarcoma HT-1080, SJSA-1 Thyroid 8505C, FTC-238 Uterine ECC-1, MFE-280 * Note: Specially requested lines can be developed if a model of interest is not among those listed above.
MODELS WITHOUT PROFILE
Although the models listed below have not yet been profiled for response to current standards of care, tumor growth curve data is available.
Histotype Cell Line* Adrenal H295R Bladder RT112 Gastric MKN-45 Leukemia NALM-6 Lung COR-L23, NCI-H1963, H2009, H1581, H1993, H441 Melanoma CHL-1, COLO 800, IGR-1, IGR-37 Multiple Myeloma MM1.s, KMS-11 Prostate LNCaP, VCaP Thyroid K1 Uterine HEC-1-A, HEC-1-B * Note: Specially requested lines can be developed if a model of interest is not among those listed above.
Efficacy evaluation in CDX models can be combined with:
- Hematology (CBC/Diff) analysis
- Pharmacokinetic or bioavailability sampling and analysis
- Histopathology or tissue sampling
- Biomarker screening, sampling, or evaluation
- In vivo microdialysis to determine pharmacological effects with high sensitivity and temporal resolution
Figure 2: Charles River’s CDX models have extensive standard of care data for combination design
On Demand Oncology Webinar
Integrated Approaches: Leveraging In Vitro and Ex Vivo Tools for Oncology Research.
Watch the Webinar
If you’re looking to purchase oncology research models for use in your own efficacy studies, please visit our research models pages or see our xenograft data collection for help in selecting the best animal model.
Sign up for the Oncology Fast 5 Monthly Newsletter for latest in oncology news.
Frequently Asked Questions (FAQs) for CDX Models:
What is a cell line-derived xenograft (CDX) model?
A cell line-derived xenograft or CDX model is a gold-standard model used for the research and testing of anti-cancer therapies. Human tumor samples are cultured as cell lines and implanted into mouse models to test the efficacy of anti-tumor compounds in vivo.
Why should I choose Charles River to run my cell line-derived xenograft (CDX) models?
In addition to over 200 CDX models, Charles River also has more than 80 proprietary PDX-derived cell line models across the full range of tumor histotypes, providing full translational relevance into the clinic.
- How can Charles River’s integrated oncology services help my study?